Key statistics
On Friday, Apellis Pharmaceuticals Inc (1JK:DUS) closed at 27.62, 23.23% above the 52 week low of 22.41 set on Nov 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.32 |
---|---|
High | 27.62 |
Low | 26.29 |
Bid | 27.91 |
Offer | 28.07 |
Previous close | 26.47 |
Average volume | 409.50 |
---|---|
Shares outstanding | 124.39m |
Free float | 107.01m |
P/E (TTM) | -- |
Market cap | 3.73bn USD |
EPS (TTM) | -2.04 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
- Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
- Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
- Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
- Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
- Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
- Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
More ▼